Skip to main content
SpringerLink
Log in

Treatment of patients with advanced non-small cell lung cancer

Importance of symptom management and attention to quality of life or clinical benefit

  • Leading Article
  • Published:
American Journal of Cancer

Abstract

In advanced non-small cell lung cancer (NSCLC), an objective response to chemotherapy is of limited value and the impact of chemotherapy on survival is modest. Therefore, endpoints evaluating the patients’ subjective benefit such as symptom control (SC), quality of life (QOL) or clinical benefit (CB) have recently been implemented into clinical trials, mostly as secondary endpoints.

Chemotherapy offers SC, not only in patients with an objective response, but also in a proportion of patients with disease stabilization. For this purpose, three to four cycles of platinum-based chemotherapy are recommended.

Interpretation of QOL objectives is limited by several methodologic problems. Studies comparing best supportive care alone with either older platinum-based combinations or single-agent chemotherapy with a new cytotoxic drug usually indicate improved survival and improvement of some component(s) of QOL in the active treatment arm. However, results from studies comparing different chemotherapies are less definitive. Trials comparing single-agent therapy with a new drug with new combinations mostly report no difference in QOL. In addition, most trials comparing new platinum-based combinations with older ones, and trials comparing new platinum-based regimens fail to show any differences in QOL. As a whole, it is far from clear whether combination therapy is superior to modern single-agent therapy, when the patient’s benefit is the primary endpoint. Non-platinum-based doublets, compared with platinum-based doublets, may lead to slightly inferior survival, are not always less toxic, and have not been proven to provide better QOL outcomes.

The CB response, originally reported in pancreatic cancer, measures more than SC, but not full QOL. Encouraging experience with this tool was reported in advanced NSCLC.

Randomized studies designed to look at some form of patient benefit as a primary endpoint should be a priority in advanced NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Souquet P, Chauvin F, Boissel S, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19–21

    Article  PubMed  CAS  Google Scholar 

  2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899–909

    Article  Google Scholar 

  3. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11: 1866–72

    PubMed  CAS  Google Scholar 

  4. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998; 317: 771–5

    Article  PubMed  CAS  Google Scholar 

  5. Hollen PJ, Gralla RJ, Kris MG, et al. Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 1999; 7: 140–8

    Article  PubMed  CAS  Google Scholar 

  6. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995; 71: 366–70

    Article  PubMed  CAS  Google Scholar 

  7. Cullen MH, Joshi R, Chetiyawardana AD, et al. Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer 1988; 58: 359–61

    Article  PubMed  CAS  Google Scholar 

  8. Osoba D, Rusthoven JJ, Turnbull KA, et al. Combination chemotherapy with bleomycin, etoposide, and cispiatin in metastatic non-small cell lung cancer. J Clin Oncol 1985; 3: 1478–85

    PubMed  CAS  Google Scholar 

  9. Tummarello D, Graziano F, Isidori P, et al. Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cispiatin, vinblastine and mitomycin-C. Cancer Chemother Pharmacol 1995; 35: 249–53

    Article  PubMed  CAS  Google Scholar 

  10. Fernandez C, Rosell R, Abad-Esteve A, et al. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol 1989; 28: 29–33

    Article  PubMed  CAS  Google Scholar 

  11. Hardy J, Noble T, Smith I. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cispiatin) in advanced non-small cell lung cancer. Cancer 1989; 60: 764–6

    Article  CAS  Google Scholar 

  12. Thatcher N, Jayson G, Bradley B, et al. Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer. Semin Oncol 1997; 24: 6S–12S

    Google Scholar 

  13. Jassem J, Krzakowski M, Roszkowski K, et al. A phase II study of gemcitabine plus cispiatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life. Lung Cancer 2002; 35: 73–9

    Article  PubMed  Google Scholar 

  14. Lippe P, Silva RR, Giuliodori L, et al. Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patients. Anticancer Res 2002; 22: 1053–9

    PubMed  CAS  Google Scholar 

  15. Gridelli C, Perrone F, Palmeri S, et al. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cispiatin (MVP) in stage IV non-small-cell lung cancer: a phase III multicentre randomised trial. Ann Oncol 1996; 7: 821–6

    Article  PubMed  CAS  Google Scholar 

  16. Vansteenkiste J, Vandebroek J, Nackaerts K, et al. Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: analysis of a randomised study. Lung Cancer 2003; 40: 191–9

    Article  PubMed  Google Scholar 

  17. Smith IE, O’Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001; 19: 1336–43

    PubMed  CAS  Google Scholar 

  18. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76

    Article  PubMed  CAS  Google Scholar 

  19. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12: 199–220

    Article  PubMed  CAS  Google Scholar 

  20. Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 1993; 29A: S51–8

    Article  PubMed  Google Scholar 

  21. Schipper H, Clinch J, McMurray A, et al. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 1984; 2: 472–83

    PubMed  CAS  Google Scholar 

  22. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 1981; 34: 585–97

    Article  PubMed  CAS  Google Scholar 

  23. De Haes JC, Van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034–8

    Article  PubMed  Google Scholar 

  24. Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol 1998; 16: 3662–73

    PubMed  CAS  Google Scholar 

  25. Kuttner L, LePage T. Face scales for the assessment of pediatric pain: a critical review. Can J Behav Sci 2003; 21: 198–209

    Google Scholar 

  26. Hollen PJ, Gralla RJ. Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol 1996; 23: 31S–40S

    Google Scholar 

  27. Kemmler G, Holzner B, Kopp M, et al. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy — general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol 1999; 17: 2932–40

    PubMed  CAS  Google Scholar 

  28. Helsing M, Bergman B, Thaning L, et al. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only: a multi-centre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 1998; 34: 1036–44

    Article  PubMed  CAS  Google Scholar 

  29. Thongprasert S, Sanguanmitra P, Juthapan W, et al. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999; 24: 17–24

    Article  PubMed  CAS  Google Scholar 

  30. Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1995; 91: 66–72

    Article  Google Scholar 

  31. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Br J Cancer 2000; 83: 447–53

    Article  PubMed  CAS  Google Scholar 

  32. Cullen MH, Billingham LJ, Woodraffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17: 3188–94

    PubMed  CAS  Google Scholar 

  33. Billingham LJ, Cullen MH. The benefits of chemotherapy in patient subgroups with unresectable non-small cell lung cancer. Ann Oncol 2001; 12: 1671–5

    Article  PubMed  CAS  Google Scholar 

  34. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 2000; 92: 1074–80

    Article  PubMed  CAS  Google Scholar 

  35. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27: 145–57

    Article  PubMed  CAS  Google Scholar 

  36. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095–103

    PubMed  CAS  Google Scholar 

  37. Dancey J, Shepherd FA, Gralla RJ, et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004; 43: 183–94

    Article  PubMed  Google Scholar 

  38. Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17: 3522–30

    PubMed  CAS  Google Scholar 

  39. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3025–34

    Article  PubMed  CAS  Google Scholar 

  40. Paccagnella A, Favaretto A, Oniga F, et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer: a multicenter, randomized phase III trial. Lung Cancer 2004; 43: 83–91

    Article  PubMed  Google Scholar 

  41. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000; 18: 122–30

    PubMed  CAS  Google Scholar 

  42. Gatzemeier U, Von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 2000; 18: 3390–9

    PubMed  CAS  Google Scholar 

  43. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 2000; 18: 2529–36

    PubMed  CAS  Google Scholar 

  44. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362–72

    Article  PubMed  CAS  Google Scholar 

  45. Giaccone G, Splinter TA, Debruyne C, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998; 16: 2133–41

    PubMed  CAS  Google Scholar 

  46. Cardenal F, Lopez Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 1999; 17: 12–8

    PubMed  CAS  Google Scholar 

  47. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18: 623–31

    PubMed  CAS  Google Scholar 

  48. Kurihara M, Shimizu H, Tsuboi K, et al. Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemo- therapy. Psychooncology 1999; 8: 355–63

    Article  PubMed  CAS  Google Scholar 

  49. Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small cell lung cancer: the Japanese Taxotere lung cancer study group. J Clin Oncol 2004; 22: 254–61

    Article  PubMed  CAS  Google Scholar 

  50. Moinpour CM, Lyons B, Grevstad PK, et al. Quality of life in advanced non-small cell lung cancer: results of a Southwest Oncology Group randomized trial. Qual Life Res 2002; 11: 115–26

    Article  PubMed  Google Scholar 

  51. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13: 1539–49

    Article  PubMed  CAS  Google Scholar 

  52. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002; 20: 4285–91

    Article  PubMed  CAS  Google Scholar 

  53. Fossella F, Pereira JR, Von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21: 3016–24

    Article  PubMed  CAS  Google Scholar 

  54. Danson S, Middleton MR, O’Byrne KJ, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced non-small cell lung carcinoma. Cancer 2003; 98: 542–53

    Article  PubMed  CAS  Google Scholar 

  55. Smit EF, Van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group — EORTC 08975. J Clin Oncol 2003; 21: 3909–17

    Article  PubMed  CAS  Google Scholar 

  56. Wachters FM, Van Putten JW, Kramer H, et al. First-line gemcitabine with cisplatin or epirubicin in advanced non-small cell lung cancer: a phase III trial. Br J Cancer 2003; 89: 1192–9

    Article  PubMed  CAS  Google Scholar 

  57. Burns HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403–13

    Google Scholar 

  58. Vansteenkiste JF, Vandebroek JE, Nackaerts KL, et al. Clinical benefit response in advanced non-small cell lung cancer: a multicenter prospective randomized phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 2001; 12: 1221–30

    Article  PubMed  CAS  Google Scholar 

  59. Jett JR, Su JQ, Krook JE, et al. Measurable or assessable disease in lung cancer trials: does it matter? J Clin Oncol 1994; 12: 2677–81

    PubMed  CAS  Google Scholar 

  60. De Wys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980; 69: 491–7

    Article  Google Scholar 

Download references

Acknowledgments

Johan F. Vansteenkiste is the holder of the Eli-Lilly L. Hertel Chair in Respiratory Oncology and the Amgen Fund in Supportive Care at the Catholic University Leuven, Belgium. There are no other sources of funding directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Respiratory Oncology Unit (Pneumology) and Leuven Lung Cancer Group, Catholic University, Leuven, Belgium

    Christophe A. Dooms &  Johan F. Vansteenkiste

Authors
  1. Christophe A. Dooms
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johan F. Vansteenkiste
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johan F. Vansteenkiste.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dooms, C.A., Vansteenkiste, J.F. Treatment of patients with advanced non-small cell lung cancer. Am J Cancer 3, 281–290 (2004). https://doi.org/10.2165/00024669-200403050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024669-200403050-00002

Keywords

Search

Navigation